Tokyo, Japan – 29 November 2006: Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), the biopharmaceutical company, today announces that at a Pharmaceutical Pipeline Update presentation yesterday in London, Novartis, highlighting the importance of its respiratory franchise, stated that initial formulation work on QVA149 had been successfully concluded and that clinical development starts in 2007.
QVA149 is a fixed dose combination product for the treatment of COPD, an irreversible and chronic obstruction of the airways. The product combines NVA237, the once daily long acting muscarinic antagonist licensed to Novartis by Sosei in 2005, together with Novartis’ once daily long acting beta2 agonist, indacaterol.
Novartis also indicated at its presentation that it expected to file NDA submissions for both NVA237 and QVA149 in 2010.
Mr Shinichi Tamura, President & CEO of Sosei, said: "I am delighted that Novartis has confirmed the progression of QVA149 into clinical development and that both QVA149 and NVA237 are expected to file in 2010. Both products will add breadth to the options available for the treatment of COPD, the prevalence of which continues to rise.”